# Jindike's flu vaccine approval risks delisting

> China's Jindike gets flu shot approval but may miss revenue target, risking stock delisting.
- Title: Jindike's flu vaccine approval risks delisting · BigGo Finance
- Summary: China's Jindike gets flu shot approval but may miss revenue target, risking stock delisting. China's Jindike faces delisting risk after full-year revenue may…
- Keywords: jindike, shanghai stock exchange, world health organization, trivalent flu vaccine, quadrivalent flu vaccine, delisting risk warning, financial losses, finance, markets, Jindike's, flu, vaccine
- Source: BigGo Finance — https://finance.biggo.com/news/84fb3fdf-985b-4c44-8903-85e857db7e1f
- Author: BigGo Finance
- Published: 2026-10-10T15:05:17+00:00
- Read time: 1 min
- Topics: jindike, shanghai stock exchange, world health organization, trivalent flu vaccine, quadrivalent flu vaccine, delisting risk warning, financial losses, finance, markets
## Jindike wins flu vaccine approval
China's Jindike received marketing approval for its trivalent influenza vaccine after WHO revised recommended strains.

> China's Jindike has received marketing approval for its trivalent influenza vaccine, filling a product gap left by the withdrawal of quadrivalent vaccines after the World Health Organization revised its recommended strain composition.
## Limited sales window for flu vaccine
The trivalent vaccine requires batch release approval and government procurement bidding, leaving minimal sales time this flu season.

> Jindike acknowledged that the trivalent vaccine has only just been approved, and the product must obtain a biological product batch release certificate before it can be marketed.
## Full-year revenue may fall below 100 million yuan
Jindike expects full-year revenue to fall below 100 million yuan (approximately $15.0 million) with no profit prospects.

> Jindike expects full-year revenue may fall below 100 million yuan (approximately $15.0 million) with no prospect of turning a profit
## Three years of consecutive losses
Jindike has posted losses for three consecutive years since 2023 with first-half 2026 revenue of 910,900 yuan.

> The company has posted losses for three consecutive years since 2023, with first-half 2026 revenue of just 910,900 yuan (approximately $140,000)
## Intense market competition
More than 20 similar trivalent flu vaccines are approved in China, intensifying competition for Jindike.

> Jindike disclosed that more than 20 trivalent influenza vaccine products have been formally approved for marketing in China
## Delisting risk warning looming
Jindike faces delisting risk if full-year revenue falls below 100 million yuan and net profit remains negative.

> if full-year revenue falls below 100 million yuan (approximately $15.0 million) and net profit is negative, the Shanghai Stock Exchange will impose a delisting risk warning
## Jindike's financial outlook
Jindike's net loss attributable to shareholders was 51.0704 million yuan with revenue down 74.15% year-on-year.

> Net loss attributable to shareholders was 51.0704 million yuan (approximately $7.6 million), with the loss widening further compared to the same period last year
## Jindike's response to challenges
Jindike is advancing post-approval work to complete product filling, packaging, and batch release quickly.

> The company is urgently advancing post-approval work to complete product filling, packaging, and batch release as quickly as possible
## Delisting risk remains high
Jindike's revenue is unlikely to exceed 100 million yuan before year-end due to limited sales window.

> Given that first-half 2026 revenue was less than 1 million yuan, even if the trivalent vaccine ramps up quickly in the fourth quarter, the difficulty of pushing full-year revenue above the 100 million yuan threshold in the remaining time is self-evident
## Key takeaway

China's Jindike faces delisting risk after full-year revenue may fall below 100 million yuan due to limited sales window and three years of losses.